Business
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
Further Supporting TTX-MC138 Application in Metastatic Cancer BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"Further Supporting TTX-MC138 Application in Metastatic Cancer\nBOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution. In the study, non-human primates (n = 4) were injected with a microdose of radiolabeled TTX-MC138 and imaged by positron emission tomography-magnetic resonance imaging (PET-MRI) to determine the pharmacokinetics and tissue distribution of the therapeutic. In addition, the pharmacodynamic activity of radiolabeled TTX-MC138 following a microdose injection was determined by measuring inhibition of the therapeutic target, miRNA-10b, using qRT-PCR. TTX-MC138 demonstrated a long circulation half-life and tissue distribution consistent with hepatic clearance. Importantly, even at a microdose, the therapeutic showed lasting activity and significantly inhibited its target, miRNA-10b, known to be a driver of metastatic progression in a number of cancers. Data from the NHP study were incorporated into a Drug Metabolism and Pharmacokinetics (DMPK) model, intended to model human exposure to TTX-MC38. The model predicted a long circulation and tissue distribution in humans, similar to results seen in preclinical studies of cancer in which complete regressions of metastatic disease were seen. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit the oncogenic RNA, microRNA-10b. MiRNA-10b is described as the master regulator of cancer progression in a number of advanced solid tumors. TransCode believes that TTX-MC138 could become a treatment for many of these cancers. Administration of TTX-MC138 has resulted in complete regression of metastatic disease in mouse models of pancreatic and breast cancer. In addition, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma. TransCode’s Chief Technology Officer, Zdravka Medarova, commented, “The latest data obtained in non-human primates support the application of TTX-MC138 for the treatment of metastatic cancer. T...